

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

08/922,240	
IFW16	
7/23/04	
	-08/922,240 1FW16 7/23/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

_ / _

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box-1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

Raw Sequence Listing Error Summary

			210. 221	
ERROR	DETECTED	SUGGESTED CORRECTION	serial number: <u>08/9</u> 22,240	
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE				
l	_Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line was retrieved in a word processor after prevent "wrapping."	"wrapped" down to the next line. This may occur if your file creating it. Please adjust your right margin to .3; this will	
2	Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.		
3, 11.	Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.		
4	Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.		
5	Variable Length	each n or Xaa can only represent a si	epresenting more than one residue. Per Sequence Rules, ngle residue. Please present the maximum number of each cate in the <220>-<223> section that some may be missing.	
6	Patentln 2.0 "bug"	sequences(s) Normally, previously coded nucleic acid sequence	PatentIn would automatically generate this section from the Please manually copy the relevant <220>-<223> section to This applies to the mandatory <220>-<223> sections for	
7	Skipped Sequences (OLD RULES)	(2) INFORMATION FOR SEQ ID NO (i) SEQUENCE CHARACTER	nal, please insert the following lines for each skipped sequence: :X: (insert SEQ ID NO where "X" is shown) ISTICS: (Do not insert any subheadings under this heading) ID NO:X: (insert SEQ ID NO where "X" is shown)	
		Please also adjust the "(ii) NUMBER C	OF SEQUENCES:" response to include the skipped sequences.	
8	Skipped Sequences (NEW RULES)	Sequence(s) missing. If intent <210> sequence id number <400> sequence id number 000	ional, please insert the following lines for each skipped sequence.	
	Use of n's or Xaa's (NEW RULES)		cted in the Sequence Listing. 20>-<223> is MANDATORY if n's or Xaa's are present. ain location of n or Xaa, and which residue n or Xaa represents.	
10	Invalid <213> Response		valid <213> responses are: Unknown, Artificial Sequence, or >-<223> section is required when <213> response is Unknown or	
11	Use of <220>	Use of <220> to <223> is MANDATO "Unknown." Please explain source of	0> "Feature" and associated numeric identifiers and responses. RY if <213> "Organism" response is "Artificial Sequence" or genetic material in <220> to <223> section. ol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12	PatentIn 2.0 "bug"	resulting in missing mandatory numeric	ion of PatentIn version 2.0. This causes a corrupted file, dentifiers and responses (as indicated on raw sequence ager" or any other manual means to copy file to floppy disk.	
13	Misuse of n/Xaa	"n" can only represent a single nucleoti	de; "Xaa" can only represent a single amino acid	



IFW16

RAW SEQUENCE LISTING

DATE: 07/23/2004

PATENT APPLICATION: US/08/922,240

TIME: 13:24:42

Input Set : A:\APBI-P01-007.TXT

Output Set: N:\CRF4\07232004\H922240.raw

```
4 <110> APPLICANT: Schreiber, Stuart L.
       5
               Belshaw, Peter
      6
               Crabtree, Gerald R.
      8 <120> TITLE OF INVENTION: GENE THERAPY BY CELL SPECIFIC TARGETING
     11 <130> FILE REFERENCE: APBI-P01-007
     13 <140> CURRENT APPLICATION NUMBER: US 08/922,240
     14 <141> CURRENT FILING DATE: 1997-08-27
     16 <150> PRIOR APPLICATION NUMBER: US 60/024,666
     17 <151> PRIOR FILING DATE: 1996-08-27
     19 <160> NUMBER OF SEQ ID NOS: 3
     21 <170> SOFTWARE: FastSEQ for Windows Version 4.0
     23 <210> SEQ ID NO: 1
     24 <211> LENGTH: 10
     25 <212> TYPE: PRT/
     26 <213> ORGANISM\ Unknown
                                              (but insufficient)

ou: alpha-aminobutyric acid

ar: sarcosine

Leu: N-methylleucine

Ala: D-alanine

Ala: D-alanine

source of genetic

material as eplanation

(see iten // on

Lun furmany

Ala: D-alanine
     28 <220> FEATURE:
     29 <223> OTHER INFORMATION: Peptide
W--> 31 <221> NAME/KEY: VARIANT
     32 <222> LOCATION: 1
     33 <223> OTHER INFORMATION: Xaa = Abu: alpha-aminobutyric acid
W--> 35 <221> VARIANT
     36 <222> LOCATION: 2
     37 <223> OTHER INFORMATION: Xaa = Sar: sarcosine
W--> 39 <221> VARIANT
     40 <222> LOCATION: 3, 5, 8, 9
     41 <223> OTHER INFORMATION: Xaa = MeLeu: N-methylleucine
W--> 43 <221> VARIANT
     44 <222> LOCATION: 7
     45 <223> OTHER INFORMATION: Xaa = D-Ala: D-alanine
W--> 47 <221> VARIANT
     48 <222> LOCATION: 10
     49 <223> OTHER INFORMATION: Xaa = Ac-N-MeValinol ester
W--> 51 <400> 1
W--> 52 Xaa Xaa Xaa Val Xaa Ala Xaa Xaa Xaa
     56 <210> SEQ ID NO: 2
     57 <211> LENGTH: 12
     58 <212> TYPE: PRT
     59 <213> ORGANISM: Unknown
     61 <220> FEATURE:
     62 <223> OTHER INFORMATION: Peptide
W--> 64 <221> NAME/KEY: VARIANT
```

65 <222> LOCATION: 1

DATE: 07/23/2004

PATENT APPLICATION: US/08/922,240 TIME: 13:24:42 Input Set : A:\APBI-P01-007.TXT Output Set: N:\CRF4\07232004\H922240.raw 66 <223> OTHER INFORMATION: Xaa = Fmoc-CpSar: 67 9-fluorenylmethoxycarbonyl-cyclopentyl sarcosine W--> 69 <221> VARIANT 70 <222> LOCATION: 2 71 <223> OTHER INFORMATION: Xaa = MeBmt: (4R)-N-methyl-4-butenyl-4-methyl-L-threonine W--> 74 <221> VARIANT 75 <222> LOCATION: 3 76 <223 > OTHER INFORMATION: Xaa = Abu: alpha-aminobutyric acid W--> 78 <221> VARIANT 79 <222> LOCATION: 4 80 <223> OTHER INFORMATION: Xaa = Sar: sarcosine W--> 82 <221> VARIANT 83 <222> LOCATION: 5, 7, 10, 11 84 <223> OTHER INFORMATION: Xaa = MeLeu: N-methylleucine W--> 86 <221> VARIANT 87 <222> LOCATION: (9)...(9) 88 <223 > OTHER INFORMATION: Xaa = D-Ala: D-alanine W--> 90 <221> VARIANT 91 <222> LOCATION: (12)...(12) 92 <223> OTHER INFORMATION: Xaa = Valinol ester W--> 94 < 400 > 2W--> 95 Xaa Xaa Xaa Xaa Xaa Val Xaa Ala Xaa Xaa Xaa 96 1 5 99 <210> SEO ID NO: 3 100 <211> LENGTH: 11 101 <212> TYPE: PRT 102 <213> ORGANISM: Unknown 104 <220> FEATURE: 105 <223> OTHER INFORMATION: Peptide W--> 107 <221> NAME/KEY: VARIANT 108 <222> LOCATION: 1 109 <223> OTHER INFORMATION: Xaa = Me-CpSar: methyl-cyclopentyl sarcosine W--> 111 <221> VARIANT 112 <222> LOCATION: 2 113 <223> OTHER INFORMATION: Xaa = MeBmt: 114 (4R) -N-methyl-4-butenyl-4-methyl-L-threonine W--> 116 <221> VARIANT 117 <222> LOCATION: 3 what about Xaa at location 9? (sel p.3) 118 <223> OTHER INFORMATION: Xaa = Abu: alpha-aminobutyric acid W--> 120 <221> VARIANT 121 <222> LOCATION: 4 122 <223> OTHER INFORMATION: Xaa = Sar: sarcosine W--> 124 <221> VARIANT 125 <222> LOCATION: 5, 7, 10 126 <223> OTHER INFORMATION: Xaa = MeLeu: N-methylleucine W--> 128 <221> VARIANT 129 <222> LOCATION: (11) ... (11) 130 <223 > OTHER INFORMATION: Xaa = MeLeu-(OH): hydroxyl-N-methylleucine

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING

DATE: 07/23/2004

PATENT APPLICATION: US/08/922,240

TIME: 13:24:42

Input Set : A:\APBI-P01-007.TXT

Output Set: N:\CRF4\07232004\H922240.raw

W--> 132 <400> 3

W--> 133 Xaa Xaa Xaa Xaa Xaa Val Xaa Ala

RAW SEQUENCE LISTING ERROR SUMMARY

DATE: 07/23/2004

PATENT APPLICATION: US/08/922,240

TIME: 13:24:43

Input Set : A:\APBI-P01-007.TXT

Output Set: N:\CRF4\07232004\H922240.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,2,3,5,7,8,9,10 Seq#:2; Xaa Pos. 1,2,3,4,5,7,6,10,11,12

Seq#:3; Xaa Pos. 1,2,3,4,5,7,9,10,11

VERIFICATION SUMMARY

DATE: 07/23/2004 PATENT APPLICATION: US/08/922,240 TIME: 13:24:43

Input Set : A:\APBI-P01-007.TXT

Output Set: N:\CRF4\07232004\H922240.raw

L:31 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order! L:35 M:258 W: Mandatory Feature missing, <220> Tag not found for SEO ID#:1 L:39 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:1 L:43 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:1 L:47 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:1 L:51 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:1 L:52 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0 L:64 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order! L:69 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:74 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:78 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:82 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:86 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:90 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:94 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:2 L:95 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0 L:107 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order! L:111 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:116 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:120 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:124~M:258~W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:128 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:132 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:133 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0